ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5080ometendo-5080Research ArticleСтатьиArticlesЭндокринные механизмы модуляции сердечнойдеятельности у пациентов с хроническойсердечной недостаточностью: роль гормона ростаEndokrinnye mekhanizmy modulyatsii serdechnoydeyatel'nosti u patsientov s khronicheskoyserdechnoy nedostatochnost'yu: rol' gormona rostaDedovI Ilibr@endocrincentr.ruBondarenkoI Ziz_bondarenko@mail.ruBezlepkinaO Bolgabezlepkina@mail.ru20101512201074№4 (2010)47Copyright © Dedov I.I., Bondarenko I.Z., Bezlepkina O.B., 20102010Dedov I.I., Bondarenko I.Z., Bezlepkina O.B.Dedov I.I., Bondarenko I.Z., Bezlepkina O.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5080

Хроническая сердечная недостаточность (ХСН) является осложнением большинства сердечно-сосудистых заболеваний. Несмотря на успешные достижения в лечении пациентов с ХСН, продолжительность их жизни в сравнении с другими заболеваниями сердца остается самой низкой, а риск внезапной смерти самым высоким. В последние годы появились данные об особенной роли гормона роста (ГР) в развитии сердечно-сосудистой патологии, а также о его возможностях в лечении терминальной стадии недостаточности кровообращения. В статье отражен обзор наиболее известных в этой области исследований.

Chronic heart failure (CHF) is a complication of most cardiovascular diseases. Despite of the last achievements in pharmacotherapy, life expectancy in patients with CHF remains to be the lowest, and the risk of sudden death is the highest. The last 20 years stressed the importance of growth hormone role in the development of cardiovascular disease, and its potential in treatment of terminal CHF. This article reviews the most well-known research conducted in this area.

хроническая сердечная недостаточностьгормон ростаcongestive heart failuregrowth hormoneReferencesAdamopoulos S., Parissis J.T., Paraskevaidis I. et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy // Eur Heart J 2003; 24: 2186-2196.Adamopoulos S., Parissis J.T., Paraskevaidis I. et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy // Eur Heart J 2003; 24: 2186-2196.Giustina A., Volterrani M., Giordano A., Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure // Am Heart J 1999; 137: 1035-43.Giustina A., Volterrani M., Giordano A., Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure // Am Heart J 1999; 137: 1035-43.Anker S.D., Swan J.W., Chua T.P., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart ailure: the importance for cardiac cachexia // Circulation 1997; 96: 526-34.Anker S.D., Swan J.W., Chua T.P., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart ailure: the importance for cardiac cachexia // Circulation 1997; 96: 526-34.Cuneo R.C., Wilmshurst P., Lowy C. et al. Cardiac failure responding to growth hormone // Lancet 1989: 838-839.Cuneo R.C., Wilmshurst P., Lowy C. et al. Cardiac failure responding to growth hormone // Lancet 1989: 838-839.Dalla Libera L., Ravara B., Volterrani M. et al. Beneficial Effects of GH/IGF-1 on Skeletal Muscle Atrophy and Function in Experimental Heart Failure // Am J Physiol Cell Physiol 2004; in press.Dalla Libera L., Ravara B., Volterrani M. et al. Beneficial Effects of GH/IGF-1 on Skeletal Muscle Atrophy and Function in Experimental Heart Failure // Am J Physiol Cell Physiol 2004; in press.Fasio S., Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy // N Engl J Med 1996; 334: 809-814.Fasio S., Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy // N Engl J Med 1996; 334: 809-814.Fasio S., Cittadini A., Sabatini D., Merola B., Colao A., Biondi B., Longobardini S. A novel mechanism of cardiac wall stress regulation in humans // European Heart Journal 1997 18: 340-347.Fasio S., Cittadini A., Sabatini D., Merola B., Colao A., Biondi B., Longobardini S. A novel mechanism of cardiac wall stress regulation in humans // European Heart Journal 1997 18: 340-347.Frustaci A., Gentiloni N., Russo M.A. Growth hormone in the treatment of dilated саrdiomyopathy // N Engl J Med 1996; 335: 672-3.Frustaci A., Gentiloni N., Russo M.A. Growth hormone in the treatment of dilated саrdiomyopathy // N Engl J Med 1996; 335: 672-3.Growth Hormone in adults. Physiological and clinical aspects. Edited by Anders Juul and Jens O.L. Jorgense // Cambridge University Press, 1996: 80-81, 98-99.Growth Hormone in adults. Physiological and clinical aspects. Edited by Anders Juul and Jens O.L. Jorgense // Cambridge University Press, 1996: 80-81, 98-99.Genth-Zotz S., Zotz R., Geil S., et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity // Circulation 1999; 99: 18-21.Genth-Zotz S., Zotz R., Geil S., et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity // Circulation 1999; 99: 18-21.Kai C. Wollter and Helmut Drexler. Growth hormone and proinflammatory cytokine activation in heart failure. Jast a new verse to an old sirens song? // Editorial. European Heart Journal 2003, 24(24): 2164-2165.Kai C. Wollter and Helmut Drexler. Growth hormone and proinflammatory cytokine activation in heart failure. Jast a new verse to an old sirens song? // Editorial. European Heart Journal 2003, 24(24): 2164-2165.Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation // Annu Rev Physiol 2003; 65: 81-101.Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation // Annu Rev Physiol 2003; 65: 81-101.McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial // Lancet 2003; 362: 767-771.McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial // Lancet 2003; 362: 767-771.Makmura H., Stanly T., Mun D et al. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity // Endocrinol. Metab. 2009; Dec 94 (12): 5131-8.Makmura H., Stanly T., Mun D et al. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity // Endocrinol. Metab. 2009; Dec 94 (12): 5131-8.Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation // Annu Rev Physiol. 2003; 65: 81-101.Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation // Annu Rev Physiol. 2003; 65: 81-101.Maryl R.J.G.Growth. Hormone therapy in patients with congestive heart failure: Need for further research (Editorial) // Am Heart J 1999; 137: 989-91.Maryl R.J.G.Growth. Hormone therapy in patients with congestive heart failure: Need for further research (Editorial) // Am Heart J 1999; 137: 989-91.Napoli R., Guardasole V., Matarazzo M. et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure // J Am Coll Cardiol. 2002; 39: 90-95.Napoli R., Guardasole V., Matarazzo M. et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure // J Am Coll Cardiol. 2002; 39: 90-95.Osterziel K.J., Strohm O., Schuler J., et al. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated ardiomyopathy // Lancet 1998; 351: 1233-7.Osterziel K.J., Strohm O., Schuler J., et al. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated ardiomyopathy // Lancet 1998; 351: 1233-7.Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure // J Am Coll Cardiol. 1992; 20: 248-254.Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure // J Am Coll Cardiol. 1992; 20: 248-254.Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., Chanson P. Impact of Growth Gormone (GH) treatment on cardiovascular risk factors in GH-deficients adults: a metaanalysis of blinded, randomized, placebo-contrrolleв trials // The Journal of Clinical Endocrinology and Metabolism 2004; 89(5): 2192-2199.Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., Chanson P. Impact of Growth Gormone (GH) treatment on cardiovascular risk factors in GH-deficients adults: a metaanalysis of blinded, randomized, placebo-contrrolleв trials // The Journal of Clinical Endocrinology and Metabolism 2004; 89(5): 2192-2199.Ross C.C., Editorial. GH and Cardiac Failure // J. Clin Endocrinol Metab, October 2001, 86(10): 4635-4637.Ross C.C., Editorial. GH and Cardiac Failure // J. Clin Endocrinol Metab, October 2001, 86(10): 4635-4637.Sacca L. Growth hormone: a new therapy for heart failure? // Baillieres Clin Endocrinol Metab 1998; 12: 217-231.Sacca L. Growth hormone: a new therapy for heart failure? // Baillieres Clin Endocrinol Metab 1998; 12: 217-231.Stefan D.A., Volterrani M., Pflaum Cl.D., Strasburger C.J. et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone // J. Am. Coll. Cardiol. 2001; 38; 2; 443-452.Stefan D.A., Volterrani M., Pflaum Cl.D., Strasburger C.J. et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone // J. Am. Coll. Cardiol. 2001; 38; 2; 443-452.Tajima M., Weinberg E.O., Bartunek J. et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure // Circulation. 1999; 99: 127-134.Tajima M., Weinberg E.O., Bartunek J. et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure // Circulation. 1999; 99: 127-134.Thusen L., Christians JS, Sorensen K.E., Jorgensen G.L., Orskov H., Henningsen P., Increased myocardial contractility following growth hormone administration in normal man // Dan Med Bull 1988; 35: 193-196.Thusen L., Christians JS, Sorensen K.E., Jorgensen G.L., Orskov H., Henningsen P., Increased myocardial contractility following growth hormone administration in normal man // Dan Med Bull 1988; 35: 193-196.Wollert K.C., Drexler H. The role of interleukin-6 in the failing heart // Heart Fail Rev 2001; 6: 95-103.Wollert K.C., Drexler H. The role of interleukin-6 in the failing heart // Heart Fail Rev 2001; 6: 95-103.Zoe S.K., Lee, Juliana C.N.C., Vincent T.E. Yeung Plasma Insulin, Growth Hormone, Cortisol, and Central Obesity Among Young Chinese Type 2 Diabetes Patients // Diabetes Care 22: 1999; 1450-1457.Zoe S.K., Lee, Juliana C.N.C., Vincent T.E. Yeung Plasma Insulin, Growth Hormone, Cortisol, and Central Obesity Among Young Chinese Type 2 Diabetes Patients // Diabetes Care 22: 1999; 1450-1457.

The authors declare that there are no conflicts of interest present.